Evidence map›Paper›PMID 39610320›Full record

ReviewIntegrative cancer therapies

Research Progress of

Lankang Wang, Baoyi Ni, Jia Wang, Jilai Zhou, Junyi Wang, Jiakang Jiang, Yutong Sui, Yaoyao Tian, Feng Gao, Yufeng Lyu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Integrative cancer therapies. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Bioactive Flavonoids fromDrug design, development and therapy · 2026
    Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Lankang WangHeilongjiang University of Chinese Medicine, Harbin, China.ORCID 0009-0009-8754-4943
Baoyi NiHeilongjiang University of Chinese Medicine, Harbin, China.
Jia WangHongqi Hospital of Mudanjiang Medical University, Mudanjiang, China.
Jilai ZhouHeilongjiang University of Chinese Medicine, Harbin, China.
Junyi WangHeilongjiang University of Chinese Medicine, Harbin, China.
Jiakang JiangThe First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, China.
Yutong SuiShenzhen Hospital of Southern Medical University, Shenzhen, China.
Yaoyao TianHeilongjiang University of Chinese Medicine, Harbin, China.
Feng GaoMudanjiang Hospital of Chinese Medicine, Mudanjiang, China.
Yufeng LyuHongqi Hospital of Mudanjiang Medical University, Mudanjiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastrointestinal (GI) cancer stands as one of the most prevalent forms of cancer globally, presenting a substantial medical and economic burden on cancer treatment. Despite advancements in therapies, it continues to exhibit the second highest mortality rate, primarily attributed to drug resistance and post-treatment side effects. There is an urgent need for novel therapeutic approaches to tackle this persistent challenge.

Indexed as

Gastrointestinal NeoplasmsMedicine, Chinese TraditionalScutellaria baicalensisAnimalsAntineoplastic Agents, PhytogenicApoptosisCell ProliferationDrug Resistance, NeoplasmDrugs, Chinese HerbalHumansPlant ExtractsTumor MicroenvironmentAntineoplastic Agents, PhytogenicDrugs, Chinese HerbalPlant ExtractsScutellaria baicalensis extractactive ingredientsflavonoidsgastrointestinal cancermolecular mechanismScutellaria baicalensis

Identifiers

PMID39610320
PMCPMC11605761

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.